European CHMP recommends approval of cefiderocol for treatment of infections due to aerobic Gram-negative organisms

Cefiderocol, which will be available as a powder for solution for infusion, is a siderophore cephalosporin which acts by inhibiting the formation of peptidoglycan in the bacterial cell wall. It is intended for use in adults with limited treatment options.


European Medicines Agency